Trial Profile

A Phase 1 study of GS-5718 for the treatment of inflammatory bowel disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Edecesertib (Primary) ; Omeprazole
Indications Cutaneous lupus erythematosus; Inflammatory bowel diseases; Rheumatoid arthritis; Systemic lupus erythematosus
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Gilead Sciences

Most Recent Events

18 Mar 2022 Results of population pharmacokinetics of GS-5718 in healthy subjects presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
09 Nov 2021 Results presented at the ACR Convergence 2021
05 Jun 2021 Status changed from recruiting to completed as per results presented at the 22nd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com